Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Alison Moskowitz, MD
Memorial Sloan Kettering Cancer Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
10 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope Cancer Center (data Collection Only)
Duarte, California, United States
Not, yet, recruiting - Stanford University Medical Center
Stanford, California, United States
Not, yet, recruiting - University of Miami
Miami, Florida, United States
Recruiting - Memorial Sloan Kettering Basking Ridge
Basking Ridge, New Jersey, United States
Recruiting - Memorial Sloan Kettering Monmouth
Middletown, New Jersey, United States
Recruiting - Memorial Sloan Kettering Bergen
Montvale, New Jersey, United States
Recruiting - Memorial Sloan Kettering Cancer Center @ Commack
Commack, New York, United States
Recruiting - Memorial Sloan Kettering Westchester
Harrison, New York, United States
Recruiting - Memorial Sloan Kettering Cancer Center
New York, New York, United States
Alison Moskowitz, MDRecruiting - Memorial Sloan Kettering Nassau
Uniondale, New York, United States
Recruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 1 Aug 2018
- Primary completion
- 31 Aug 2026
- Completion
- 31 Aug 2026
- Last update posted
- 29 Jun 2026
- Registered enrollment
- 257
- Registry id
- NCT03618550
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.